Literature DB >> 29561299

Motor Dysfunction as a Risk Factor for Conversion to Psychosis Independent of Medication Use in a Psychosis-Risk Cohort.

Michael D Masucci1, Amanda Lister, Cheryl M Corcoran, Gary Brucato, Ragy R Girgis.   

Abstract

The Structured Interview for Psychosis-Risk Syndromes (SIPS) contains criteria for the Attenuated Positive Symptom Syndrome (APSS), a period of subthreshold positive symptoms that predates full-blown psychosis. Motor abnormalities are often associated with these symptoms but have not been adequately studied. We assessed a diverse sample of 192 APSS participants (27.1% female; 47.9% white; mean age = 20.03 years) for motor dysfunction (SIPS G.3. score) at baseline and conversion to psychosis every 3 months for up to 2 years. Fifty-nine (30.7%) participants converted to psychosis. Baseline G.3. score was significantly higher among converters than nonconverters (mean difference = 0.66; t[95.929] = 2.579, p < 0.05). No significant differences in baseline G.3. were found between demographic groups or those with differential medication use. These results point to the use of G.3. as a potential predictor of psychosis among APSS individuals and potentially implicate the shared biological underpinnings of motor dysfunction in the APSS and full-blown psychotic illnesses.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29561299      PMCID: PMC5899031          DOI: 10.1097/NMD.0000000000000806

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  41 in total

1.  Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability.

Authors:  Tandy J Miller; Thomas H McGlashan; Joanna L Rosen; Kristen Cadenhead; Tyrone Cannon; Joseph Ventura; William McFarlane; Diana O Perkins; Godfrey D Pearlson; Scott W Woods
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

2.  Abnormalities in hemispheric specialization of caudate nucleus connectivity in schizophrenia.

Authors:  Sophia Mueller; Danhong Wang; Ruiqi Pan; Daphne J Holt; Hesheng Liu
Journal:  JAMA Psychiatry       Date:  2015-06       Impact factor: 21.596

3.  Baseline demographics, clinical features and predictors of conversion among 200 individuals in a longitudinal prospective psychosis-risk cohort.

Authors:  G Brucato; M D Masucci; L Y Arndt; S Ben-David; T Colibazzi; C M Corcoran; A H Crumbley; F M Crump; K E Gill; D Kimhy; A Lister; S A Schobel; L H Yang; J A Lieberman; R R Girgis
Journal:  Psychol Med       Date:  2017-03-02       Impact factor: 7.723

4.  Childhood videotaped social and neuromotor precursors of schizophrenia: a prospective investigation.

Authors:  Jason Schiffman; Elaine Walker; Morten Ekstrom; Fini Schulsinger; Holger Sorensen; Sarnoff Mednick
Journal:  Am J Psychiatry       Date:  2004-11       Impact factor: 18.112

5.  Increased risk of schizophrenia from additive interaction between infant motor developmental delay and obstetric complications: evidence from a population-based longitudinal study.

Authors:  Mary C Clarke; Antti Tanskanen; Matti Huttunen; David A Leon; Robin M Murray; Peter B Jones; Mary Cannon
Journal:  Am J Psychiatry       Date:  2011-09-02       Impact factor: 18.112

6.  Adolescents and adults at clinical high-risk for psychosis: age-related differences in attenuated positive symptoms syndrome prevalence and entanglement with basic symptoms.

Authors:  M Gerstenberg; A Theodoridou; N Traber-Walker; M Franscini; D Wotruba; S Metzler; M Müller; D Dvorsky; C U Correll; S Walitza; W Rössler; K Heekeren
Journal:  Psychol Med       Date:  2015-12-16       Impact factor: 7.723

7.  Longitudinal progression of movement abnormalities in relation to psychotic symptoms in adolescents at high risk of schizophrenia.

Authors:  Vijay A Mittal; Craig Neumann; Mary Saczawa; Elaine F Walker
Journal:  Arch Gen Psychiatry       Date:  2008-02

Review 8.  Developmentally moderated expressions of the neuropathology underlying schizophrenia.

Authors:  E F Walker
Journal:  Schizophr Bull       Date:  1994       Impact factor: 9.306

9.  Meta-analyses of cognitive and motor function in youth aged 16 years and younger who subsequently develop schizophrenia.

Authors:  H Dickson; K R Laurens; A E Cullen; S Hodgins
Journal:  Psychol Med       Date:  2011-09-06       Impact factor: 7.723

10.  Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study.

Authors:  Oliver D Howes; Subrata K Bose; Federico Turkheimer; Isabel Valli; Alice Egerton; Lucia R Valmaggia; Robin M Murray; Philip McGuire
Journal:  Am J Psychiatry       Date:  2011-07-18       Impact factor: 18.112

View more
  5 in total

1.  Sensorimotor and Activity Psychosis-Risk (SMAP-R) Scale: An Exploration of Scale Structure With Replication and Validation.

Authors:  Katherine S F Damme; Jason Schiffman; Lauren M Ellman; Vijay A Mittal
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

2.  Multiple Network Dysconnectivity in Adolescents with Psychotic Experiences: A Longitudinal Population-Based Study.

Authors:  Aisling O'Neill; Eleanor Carey; Niamh Dooley; Colm Healy; Helen Coughlan; Clare Kelly; Thomas Frodl; Erik O'Hanlon; Mary Cannon
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

3.  Postural Sway Abnormalities in Schizotypal Personality Disorder.

Authors:  Deborah Apthorp; Amanda R Bolbecker; Lisa A Bartolomeo; Brian F O'Donnell; William P Hetrick
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

4.  Interactions between the cortical midline structures and sensorimotor network track maladaptive self-beliefs in clinical high risk for psychosis.

Authors:  Henry R Cowan; Katherine S F Damme; Vijay A Mittal
Journal:  Schizophrenia (Heidelb)       Date:  2022-09-16

5.  Cerebellar and basal ganglia motor network predicts trait depression and hyperactivity.

Authors:  T Bryan Jackson; Jessica A Bernard
Journal:  Front Behav Neurosci       Date:  2022-09-16       Impact factor: 3.617

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.